Annual report
3055.TEDINET S100W54R
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥289.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥275.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥262.6bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥239.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.9bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.9bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.5bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥147.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥147.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥137.9bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥136.9bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥133.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥85.6bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥86.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥61.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥60.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.4bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥54.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥20.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥262m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥828m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥990m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥898m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥835m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥731m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥116.44 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.2 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.41 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.01 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,942.63 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,819.99 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,614.23 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,460.67 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,346.36 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 41.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,605 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,601 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,626 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 1,625 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,570 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥1.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥1.9bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥320m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥382m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥411m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥472m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥799m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥289m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥785m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥411m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥337m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥407m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥334m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥619m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥637m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥43.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥44.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥44.4bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥44.5bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥44.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.3bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥41.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.9bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥42.9bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥43.1bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥19.19 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.39 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.36 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.27 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.33 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥20 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,984.17 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,986.27 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,955.09 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,900.56 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,859.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 97.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 24,400,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 59 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 58 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 63 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 62 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | capex | 2024-04-01 → 2025-03-31 | ¥33m |
| Otherother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥28m |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥57m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Otherother segments | segment assets | at 2025-03-31 | ¥43.2bn |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥325m |
| Dispensing Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥102m |
| Dispensing Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥80m |
| Dispensing Industryreportable segment | employees | at 2025-03-31 | 308 pure |
| Dispensing Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.8bn |
| Dispensing Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.8bn |
| Dispensing Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥11m |
| Dispensing Industryreportable segment | segment assets | at 2025-03-31 | ¥6.1bn |
| Dispensing Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥105m |
| Information And Communication Technology Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥13m |
| Information And Communication Technology Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥26m |
| Information And Communication Technology Industryreportable segment | employees | at 2025-03-31 | 80 pure |
| Information And Communication Technology Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥895m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Information And Communication Technology Industryreportable segment | segment assets | at 2025-03-31 | ¥1.0bn |
| Information And Communication Technology Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥18m |
| Medical Equipment Wholesale Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥301m |
| Medical Equipment Wholesale Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥254m |
| Medical Equipment Wholesale Industryreportable segment | employees | at 2025-03-31 | 424 pure |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥70.0bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥69.5bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥536m |
| Medical Equipment Wholesale Industryreportable segment | segment assets | at 2025-03-31 | ¥28.1bn |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Nursing Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥152m |
| Nursing Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥230m |
| Nursing Industryreportable segment | employees | at 2025-03-31 | 257 pure |
| Nursing Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Nursing Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Nursing Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10m |
| Nursing Industryreportable segment | segment assets | at 2025-03-31 | ¥5.6bn |
| Nursing Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥319m |
| Wholesaler Of Drugs Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Wholesaler Of Drugs Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥525m |
| Wholesaler Of Drugs Industryreportable segment | employees | at 2025-03-31 | 467 pure |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥209.7bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥201.9bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥7.8bn |
| Wholesaler Of Drugs Industryreportable segment | segment assets | at 2025-03-31 | ¥99.2bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥301.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥289.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥183.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Otherother segments | capex | 2023-04-01 → 2024-03-31 | ¥48m |
| Otherother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥36m |
| Otherother segments | revenue | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Otherother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥57m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Otherother segments | segment assets | at 2024-03-31 | ¥44.5bn |
| Otherother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥384m |
| Dispensing Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥144m |
| Dispensing Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥73m |
| Dispensing Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥13.3bn |
| Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥13.3bn |
| Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12m |
| Dispensing Industryreportable segment | segment assets | at 2024-03-31 | ¥6.3bn |
| Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥120m |
| Information And Communication Technology Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥11m |
| Information And Communication Technology Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥25m |
| Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥595m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Information And Communication Technology Industryreportable segment | segment assets | at 2024-03-31 | ¥858m |
| Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥39m |
| Medical Equipment Wholesale Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥160m |
| Medical Equipment Wholesale Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥221m |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥66.5bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥66.0bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥527m |
| Medical Equipment Wholesale Industryreportable segment | segment assets | at 2024-03-31 | ¥27.7bn |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.3bn |
| Nursing Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥177m |
| Nursing Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥223m |
| Nursing Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Nursing Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8m |
| Nursing Industryreportable segment | segment assets | at 2024-03-31 | ¥5.6bn |
| Nursing Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥326m |
| Wholesaler Of Drugs Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Wholesaler Of Drugs Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥484m |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥199.5bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥191.1bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8.4bn |
| Wholesaler Of Drugs Industryreportable segment | segment assets | at 2024-03-31 | ¥98.5bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥287.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥275.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥183.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,965
| Item | Context | Value | Unit |
|---|---|---|---|
| Subsidies received inv cf | CurrentYearDuration | 306000000 | JPY |
| Payments for retirement of noncurrent assets inv cf | Prior1YearDuration | -1000000 | JPY |
| Payments for retirement of noncurrent assets inv cf | CurrentYearDuration | -11000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -2039000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -1821000000 | JPY |
| Decrease in short term loans payable fin cf | Prior1YearDuration | － | JPY |
| Decrease in short term loans payable fin cf | CurrentYearDuration | -15000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -1000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -34000000 | JPY |
| Decrease increase in treasury stock fin cf | Prior1YearDuration | -320000000 | JPY |
| Decrease increase in treasury stock fin cf | CurrentYearDuration | -431000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -488000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -426000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -87000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -83000000 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -898000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -990000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 2790000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | -3073000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 18022000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 20813000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 20813000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 17739000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 15 | |
| Number of associates accounted for using equity method | CurrentYearInstant | 3 | |
| Receivables from contracts with customers ca | Prior1YearInstant | 56412000000 | JPY |
| Receivables from contracts with customers ca | CurrentYearInstant | 57975000000 | JPY |
| Contract assets | Prior1YearInstant | 438000000 | JPY |
| Contract assets | CurrentYearInstant | 279000000 | JPY |
| Contract liabilities | Prior1YearInstant | 357000000 | JPY |
| Contract liabilities | CurrentYearInstant | 360000000 | JPY |
| Write downs of inventories | Prior1YearDuration | 724000000 | JPY |
| Write downs of inventories | CurrentYearDuration | 386000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 191141000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 66009000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03003-000DispensingIndustryReportableSegmentsMember | 13276000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03003-000NursingIndustryReportableSegmentsMember | 4284000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 595000000 | JPY |
| Revenues from external customers | Prior1YearDuration_OtherReportableSegmentsMember | 57000000 | JPY |
| Revenues from external customers | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 275364000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 8353000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03003-000MedicalEquipmentWholesaleIndustryReportableSegmentsMember | 527000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03003-000DispensingIndustryReportableSegmentsMember | 12000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03003-000NursingIndustryReportableSegmentsMember | 8000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E03003-000InformationAndCommunicationTechnologyIndustryReportableSegmentsMember | 1005000000 | JPY |
| Transactions with other segments | Prior1YearDuration_OtherReportableSegmentsMember | 1747000000 | JPY |
| Transactions with other segments | Prior1YearDuration_TotalOfReportableSegmentsAndOthersMember | 11655000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E03003-000WholesalerOfDrugsIndustryReportableSegmentsMember | 199495000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |